The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.

Sara  Tolaney

Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi

(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences

Evandro  de Azambuja

Honoraria - AstraZeneca; Gilead Sciences; Libbs (Inst); Lilly; MSD Oncology; Novartis/Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech; SeaGen; Zodiac Pharma

Consulting or Advisory Role - AstraZeneca (Inst); Libbs; Novartis; Pierre Fabre; Roche/Genentech

Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences

(OPTIONAL) Uncompensated Relationships - Belgian Society of Medical Oncology (BSMO); ESMO

Kevin  Kalinsky

Employment - EQRx (I)

Stock and Other Ownership Interests  - EQRx (I)

Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; mersana; Mersana; Myovant Sciences; Novartis; Pfizer; Prelude Therapeutics; ProteinQure; Puma Biotechnology; RayzeBio; Regor; Relay Therapeutics; Takeda

Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)

Sherene  Loi

Honoraria - Adanate; Amaroq Therapeutics; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Domain Therapeutics; Exact Sciences; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Roche/Genentech; SAGA Diagnostics

Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - BMS

Other Relationship - Roche Medical writing support

Sung-Bae  Kim

Stock and Other Ownership Interests  - Genopeaks

Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences

Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Ensol Biosciences; ISU Abxis; Lilly (Inst); OBI Pharma

Research Funding - Genzyme (Inst)

Clinton  Yam

Stock and Other Ownership Interests  - Cytodyn

Consulting or Advisory Role - Gilead Sciences

Research Funding - Amgen (Inst); BostonGene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst)

Travel, Accommodations, Expenses - Gilead Sciences

Bernardo  Rapoport

Consulting or Advisory Role - Acino Pharma South Africa; Astellas Pharma; Astra-Zeneca South Africa; Eisai South Africa; Janssen; Lilly South Africa; Merck; Novartis South Africa; Pfizer South Afrtica; Roche; Sandoz/Hexal; Takeda South Africa

Speakers' Bureau - Acino Pharma South Africa; Astellas Pharma; AstraZeneca; Eisai South Africa; Janssen Oncology South Africa; Lilly South Africa; MSD Oncology; Novartis South Africa; Pfizer South Africa; Roche; Sandoz/Hexal; Takeda

Seock-Ah  Im

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech

Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Other Relationship - Roche

(OPTIONAL) Uncompensated Relationships - Roche

Barbara  Pistilli

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Myriad Genetics; Novartis; Olema Oncology (Inst); PIERRE FABRE; Puma Biotechnology

Research Funding - AstraZeneca (Inst); DAIICHI-SANKYO (Inst); Gilead Sciences (Inst); Merus (Inst); Pfizer (Inst); Puma Biotechnology (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; MSD Oncology; Novartis; Pfizer; Pierre Fabre

Wassim  McHayleh

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Natera

Speakers' Bureau - Agendia; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Merck; Natera; Pfizer; Stemline Therapeutics

David  Cescon

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; GenomeRx; Gilead Sciences; GlaxoSmithKline; INFLEX; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics

Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Guardant Health (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); ProteinQure (Inst); Roche/Genentech (Inst)

Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.

Expert Testimony - AstraZeneca

(OPTIONAL) Uncompensated Relationships - Inivata/NeoGenomics

Junichiro  Watanabe

Honoraria - AstraZeneca; Chugai Pharma; Eisai; Exact Sciences; Gilead Sciences; Kyowa Kirin; Lilly Japan; MSD; Pfizer

Consulting or Advisory Role - Daiichi-Sankyo; Gilead Sciences; Lilly

Research Funding - Daiichi-Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst)

Alejandro  Lara

Consulting or Advisory Role - Ipsen; MSD Oncology

Speakers' Bureau - MSD Oncology

Travel, Accommodations, Expenses - MSD Oncology; Roche

Ruffo  Freitas-Junior

Honoraria - Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Libbs; Lilly (Inst); MSD; MSD/AstraZeneca; Novartis (Inst); zeiss

Consulting or Advisory Role - Gilead Sciences; MSD Oncology; Novartis

Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); MSD (Inst); Novartis Biociencias (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Daichii Sankyo; Gilead Sciences; Libbs; MSD/AstraZeneca

Javier  Bofill

Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche

Speakers' Bureau - AstraZeneca

Travel, Accommodations, Expenses - Pfizer

Maryam  Afshari

Employment - Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences

Dianna  Gary

Employment - Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences

Travel, Accommodations, Expenses - Gilead Sciences

Catherine  Lai

Employment - Genentech/Roche; Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences; Roche/Genentech

Patents, Royalties, Other Intellectual Property - Genentech/Roche

Peter  Schmid

Employment - Roche (I)

Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics

Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)

Travel, Accommodations, Expenses - ESMO; SABS